Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
JAMA Cardiology|November 15, 2023
Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical TrialSanjiv J Shah, Nowell Fine, Pablo Garcia-Pavia, et al.
Heart (British Cardiac Society)|May 29, 2016
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysisRui Providencia, Perry Elliott, Kiran Patel, et al.
Circulation. Heart Failure|June 15, 2017
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)Mathew S Maurer, Perry Elliott, Giampaolo Merlini, et al.
Heart Failure Reviews|October 17, 2023
Electrocardiographic abnormalities in patients with cardiomyopathiesAlberto Aimo, Agnese Milandri, Andrea Barison, et al.
Frontiers in Cardiovascular Medicine|June 20, 2022
Morphological and Physiological Characteristics of Ruptured Plaques in Native Arteries and Neoatherosclerotic Segments: An OCT-Based and Computational Fluid Dynamics StudyChongying Jin, Ryo Torii, Anantharaman Ramasamy, et al.
European Journal of Heart Failure|July 9, 2020
An expert consensus document on the management of cardiovascular manifestations of Fabry diseaseAleš Linhart, Dominique P Germain, Iacopo Olivotto, et al.
European Heart Journal|November 20, 2012
Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and CanadaAnnika F M Haywood, Nancy D Merner, Kathy A Hodgkinson, et al.
ESC Heart Failure|October 13, 2025
Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CMPablo Garcia-Pavia, Francisco Javier Haro Del Moral, Francesco Cappelli, et al.
Circulation. Heart Failure|December 20, 2021
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid CardiomyopathyPerry Elliott, Brian M Drachman, Stephen S Gottlieb, et al.
Circulation|October 6, 2010
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathyKhalid Abozguia, Perry Elliott, William McKenna, et al.
Pageof 17